1.. Introduction {#S0001}
================

Necrolytic migratory erythema (NME) is a rare cutaneous paraneoplastic manifestation of glucagonoma. Glucagonoma is a tumor of alpha cells of pancreas that secret glucagon, and plays a major role in blood glucose hemostasis. Elevated glucagon level due to glucagonoma can cause a variety of clinical manifestations including weight loss, diabetes, and NME. Misdiagnosis of paraneoplastic cutaneous manifestation could delay the diagnosis of glucagonoma. Here, we present an interesting case of chronic skin rash which was treated as eczema for more than 4 years, and recently as urticarial vasculitis, which was actually NME of glucagonoma. The skin rash has resolved completely with resection of the tumor.

2.. Case description {#S0002}
====================

A 54-year-old Caucasian male with past medical history of hypertension, hyperlipidemia, insulin-dependent diabetes mellitus, and chronic skin rash presented to the emergency department (ED) with skin rash of 4-year duration that had worsened over the preceding 2 weeks. He was diagnosed with eczematous skin disease about 4 years ago and treated with topical steroid intermittently with variable response. About 2 months ago, he was started on doxycycline and oral prednisone for unremitting skin lesions. However, he had poor glycemic control with use of prednisone, and hemoglobin A1c (HbA1c) increased from 6.0% to 10.0%. A skin biopsy was done for a definitive diagnosis of this chronic skin lesion, and it was reported as urticarial vasculitis. Prednisone was discontinued for poor glycemic control, and dapsone was added. During the following 2 weeks, the rash progressed to involve both lower extremities, upper extremities, and trunk with swelling and bullae with no other identifiable trigger. In the ED, he reported of unintentional weight loss of 30 lbs in the preceding 3 months and denied any family history of malignancy or autoimmune disease. He also denied history of smoking, anorexia, or abdominal pain. On examination, the affected area of the skin was warm with diffuse erythema and edema throughout both lower extremities. Ulceration was prominent in the right lower extremity, trunk, bilateral upper extremities, and palms and soles ([Figure 1](#F0001)). There were bullae with associated paresthesia. The patient was unable to bear weight and experienced sharp shooting pain in his bilateral feet. Further work up was directed to rule out other etiologies of skin rash and weight loss, including nutritional deficiency, infection, autoimmune disease, and occult malignancy. He had elevated erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) at 32 (reference range 0--20 mm/h) and 8.05 (reference range \<1.0 mg/dl), respectively. Comprehensive work up for autoimmune disease and infectious etiology were negative. Because of his recent significant weight loss, a computed tomography (CT) scan of chest, abdomen, and pelvis with contrast was done to rule out occult malignancy, which showed a large, heterogenously enhancing mid to distal pancreatic mass measuring 9.4 × 3.8 cm with surrounding low-attenuation soft tissue thickening ([Figure 2](#F0002)). Tumor marker, CA 19--9 was 2.0 (reference range \< 35 U/ml); however, glucagon was elevated to 2,178 (normal \< 80 pg/dl). Prolactin, T4, and TSH levels were within normal range. Hemoglobin and hematocrit were low at 12.2 (reference range 13.5--16.5 gm/dl) and 36.1 (reference range 40--50%), respectively. Liver enzymes were within normal limit. There was no leukocytosis or fever, indicating cellulitis less likely.

An endoscopic ultrasound (EUS) was done which showed an isoechoic mass (6.5 cm × 3.8 cm) in the body/tail area of the pancreas, and fine needle aspiration (FNA) samples were obtained from the mass. Immunohistochemical stains were positive for synaptophysin, chromogranin, CD56, pancytokeratin, and focal positivity for glucagon suggestive of glucagonoma. He underwent distal pancreatectomy with splenectomy and cholecystectomy. Tissue specimens showed a pancreatic well-differentiated neuroendocrine tumor, WHO grade 1. The tumor cells were positive for chromogranin and synaptophysin and negative for nuclear beta-catenin. Resected margins were free of malignant involvement. None of the 26 lymph nodes collected during surgery were positive. The punch biopsy of the skin lesion showed psoriasiform inflammatory reaction and confluent parakeratosis ([Figure 3](#F0003)). The glucagon level normalized to 25 pg/ml (from 2,718 pg/ml) 5 days after the surgical resection of tumor. Dapsone and doxycycline were discontinued and the patient was discharged home. During 6-week outpatient follow up, he had complete resolution of the skin lesions.

3.. Discussion {#S0003}
==============

In 1942, Dr. Becker and his colleagues described a 45-year-old female who was hospitalized with a history of widespread pruritic erythematovesicular skin eruptions for 8 months that was unresponsive to roentgen irradiation, ultraviolet irradiation, systemic iodides, ferrous sulfate, and high vitamin diet. She died of circulatory collapse and respiratory failure due to 'shock phenomenon'. Postmortem examination revealed a pancreatic tumor replacing the tail and body of the pancreas. This is the first known reported case of association of pancreatic cancer with cutaneous manifestations \[[1](#CIT0001)\]. This characteristic skin lesion is now known as necrolytic migratory erythema (NME) due to its migratory nature, erythematous appearance, and histological findings of necrosis of the upper spinous layer \[[2](#CIT0002)\]. However, this finding in biopsy is nonspecific and can be absent or focally present on biopsy \[[3](#CIT0003)\]. In 1966, Dr. McGavran and his colleagues described the first case of glucagonoma in a 42-year-old female who presented with bullous and eczematoid dermatitis of the hands, feet, and legs \[[4](#CIT0004)\]. The diagnosis of glucagonoma is made based on increased serum glucagon level and presence of glucagon secreting tumor in the pancreas. Glucagonoma presenting with constellation of symptoms, known as glucagonoma syndrome, was described in 1974 based on the findings in nine patients presenting with NME, stomatitis, weight loss, and diabetes in seven patients \[[5](#CIT0005)\]; however, this syndrome was extensively reviewed in 1978 by Dr. Swenson and his colleagues \[[6](#CIT0006)\]. While NME is described as a characteristic cutaneous manifestation of glucagonoma, it has been reported in other diseases, such as other malignancies (e.g., hepatocellular carcinoma, bronchial carcinoma, jejunal adenocarcinoma, etc.), celiac disease, chronic pancreatitis, liver cirrhosis, inflammatory bowel disease, and nutritional deficiencies \[[7](#CIT0007)\].

NME is a cutaneous paraneoplastic manifestation of glucagonoma, and can be the only presenting feature in approximately 70% of patients \[[8](#CIT0008)\]. This rash is commonly pruritic, painful, erythematous, and well-demarcated plaques \[[9](#CIT0009),[10](#CIT0010)\], and may involve the face, trunk, extremities, and perineum \[[11](#CIT0011)\]. The biopsy of the skin lesion may show superficial epithelial necrosis of the spinous layer of epidermis and vacuolated keratinocytes; however, overlapping dermatoses such as pemphigoid, psoriasis, or eczema can sometime make the diagnosis challenging \[[2](#CIT0002)\]. High serum glucagon level due to glucagonoma has glucagon-like peptide (GLP-1) activity that causes a shift in catabolic state and caloric consumption resulting in weight loss. Direct or indirect effect of catabolic state induced by glucagon with resultant deficiency of fatty acids, amino acids, and minerals essential for epidermal growth and turnover results in the development of the characteristic findings of NME \[[12](#CIT0012)--[15](#CIT0015)\]. Intermittent amino acids and fatty acid infusion via peripheral vascular access has been reported to be successfully used to treat NME in the glucagonoma syndrome. However, other symptoms related to glucagonoma syndrome does not improve by this infusion \[[16](#CIT0016)\]. Treatment of glucagonoma with octreotide or surgical resection of tumor results in resolution of NME.

There are published reports of characteristic skin lesions that aid in diagnosis of underlying glucagonoma \[[17](#CIT0017)--[19](#CIT0019)\]; however, there are also reports of delayed diagnosis of glucagonoma due to misdiagnosis or delayed diagnosis of skin lesions ([Table 1](#T0001)). Oftentimes, the patients with glucagonoma presents with skin lesions that is diagnosed as dermatitis, psoriasis, or eczema and treated with topical and/or oral steroid with variable responses. Our patient had diabetes and skin rash for more than 4 years. His diabetes was treated with insulin, and skin rash was diagnosed as eczema by his dermatologist, and treated with topical steroid with variable response. Due to the chronicity of the rash, and not resolving in 4 years, he was treated with doxycycline and oral steroid, which caused poor glycemic control requiring discontinuation of steroid therapy. Dapsone was added by his physician due to skin biopsy findings of urticarial vasculitis; however, his rash worsened with significant weight loss requiring ED visit. His skin rash completely resolved within 6 weeks of surgical resection of the glucagonoma. This case illustrates a delayed diagnosis of glucagonoma for approximately 4 years due to misdiagnosis of his skin lesion, and not initiating further investigation of the underlying etiology in a timely manner.10.1080/20009666.2019.1671574-T0001Table 1.Delayed diagnosis of glucagonoma in patients initially presenting with skin rash \[[3](#CIT0003),[20](#CIT0020)--[24](#CIT0024)\].Age, genderInitial presenting symptom(s)Initial diagnosis of skin lesionInitial treatment for skin lesionGlucagon level at diagnosis of glucagonomaTreatment of glucagonoma and outcome of skin lesion(s)Delay in diagnosis of glucagonoma from initial presentation53 yo, FemaleSkin rash in extremities, genitalia and oral cavity.Erosive and bullous skin lesionTopical steroids2,040 ng/lResection of the tumor, but patient died after 28 days due to comorbidities.1 year55 yo, MaleSkin rash in the face, upper and lower extremities and perianal area.EczemaOral prednisone1,625 ng/lResection of tumor and disappearance of skin lesion 1 week after surgery2 years63 yo, FemalePruritic skin rash in groin, abdomen, axilla, gluteal region, calves and anklesSpongiotic dermatitis, zinc deficiency dermatitisTopical steroid, zinc supplement3,000 ng/lResection of tumor, disappearance of skin lesions3 years60 yo, MaleSkin rash in lower legs, thighs, abdomen, lower back, head, face, hands and feetSystemic pruritus and erythema, dermatitisSymptomatic treatment648 ng/lResection of the tumor, resolution of the skin lesions3 years54 yo, MalePruritic macule and bullae in the scalp, scrotum, perineum and distal extremitiesPsoriasisVitamin supplement, coriodermia, ozonotherapy490 ng/lResection of the tumor, complete resolution of skin lesion 2 days postoperatively.2 years

In conclusion, unremitting skin lesions associated with diabetes/hyperglycemia and/or weight loss needs further investigations to rule out other etiologies including nutritional deficiencies, specially zinc, vitamins, and iron; infectious etiology and occult malignancies. If glucagon level is elevated, an abdominal imaging is needed to localize the source of glucagon-secreting tumor. A high degree of clinical suspicion is necessary for early diagnosis of glucagonoma because of the rarity of the disease as well as association with nonspecific skin lesions. 10.1080/20009666.2019.1671574-F0001Figure 1.Affected area of the skin showed desquamation, erythema, and ulceration in lower extremities and sole. 10.1080/20009666.2019.1671574-F0002Figure 2.A CT scan with contrast of abdomen showed a large, heterogenously enhancing mid to distal pancreatic mass measuring 9.4 × 3.8 cm with surrounding low-attenuation soft tissue thickening (white arrows). 10.1080/20009666.2019.1671574-F0003Figure 3.A biopsy of skin lesion showing psoriasiform inflammatory reaction and confluent parakeratosis.
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